Jiaqiang Cai
Co-founder ,Chief Scientific Officer & Co-Chief Executive Officer Medilink Therapeutics
Dr. Cai is the Co-founder, CSO and Co-CEO of MediLink Therapeutics. Before cofounding Medilink Therapeutics, Dr. Cai served as vice general manager and director of chemistry of Shanghai Hansoh Pharm. Before joining Hansoh, Dr Cai was deputy general manager of Sichuan Kelun Institute of Pharmaceutical Research responsible for small molecule drug R&D and Kelun’s innovation centre managing over 250 research scientists. Dr. Cai accumulated over 30 years of experience in drug discovery research, managed over 100 projects across different therapeutic areas with over 30 compounds in clinical development or commercial stages, nearly 20 of them are antibody drug conjugates, including SKB264, YL201 and YL202.
Seminars
- Highlighting current non-internalizing ADC linker-payload technologies and its challenges
- Demonstrating in vitro and in vivo mechanistic studies with TMALIN ADC technology
- Sharing clinical product examples from TMALIN linker-payload technology to achieve better efficacy, low toxicity and a bigger ADC target space